VINDESINE AND ICRF-159 COMBINATION CHEMOTHERAPY

被引：0
|
作者：
STEVENS, EE [1 ]
EINHORN, LH [1 ]
ROHN, RJ [1 ]
机构：
[1] INDIANA UNIV,MED CTR,INDIANAPOLIS,IN 46223
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1980年 / 21卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [31] RAZOXANE (ICRF-159) DELAYS APPEARANCE OF COLORECTAL LIVER METASTASES
    TAYLOR, RH
    GILBERT, JM
    EVANS, MGC
    LANE, HG
    GUT, 1985, 26 (05) : A572 - A572
  • [32] BIOLOGICAL PROPERTIES OF ICRF-159 AND RELATED BIS(DIOXOPIPERAZINE) COMPOUNDS
    HERMAN, EH
    WITIAK, DT
    HELLMANN, K
    WARAVDEKAR, VS
    ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY, 1982, 19 : 249 - 290
  • [33] INHIBITION OF CARDIOTOXIC, NEPHROTOXIC AND NEUROTOXIC EFFECTS OF DOXORUBICIN BY ICRF-159
    HU, ST
    BRANDLE, E
    ZBINDEN, G
    PHARMACOLOGY, 1983, 26 (04) : 210 - 220
  • [34] BIS-DIKETOPIPERAZINE DERIVATIVES IN CLINICAL ONCOLOGY - ICRF-159
    POSTER, DS
    PENTA, J
    MARSONI, S
    BRUNO, S
    MACDONALD, JS
    CANCER CLINICAL TRIALS, 1980, 3 (04) : 315 - 320
  • [35] TREATMENT OF LYMPHOMATA WITH ICRF 159 (NSC 129943) ADJUNCTIVE TO COMBINATION CHEMOTHERAPY
    GARRETT, MJ
    DAS, S
    IRISH MEDICAL JOURNAL, 1977, 70 (15) : 460 - 461
  • [36] COMBINATION CHEMOTHERAPY OF ADVANCED COLO-RECTAL CANCER WITH TRIAZINATE (T) AND ICRF-159 (I) AFTER FAILURE OF 5-FLUOROURACIL (F)
    CHIUTEN, D
    VOGL, SE
    KAPLAN, BH
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 103 - 103
  • [37] ICRF-159对柔毛霉素药效的影响
    王德昌
    国外医学参考资料(肿瘤学分册), 1975, (01) : 23 - 23
  • [38] PHASE-II EVALUATION OF DIBROMODULCITOL, ICRF-159, AND MAYTANSINE FOR SARCOMAS
    BORDEN, EC
    ASH, A
    ENTERLINE, HT
    ROSENBAUM, C
    LAUCIUS, JF
    PAUL, AR
    FALKSON, G
    LERNER, H
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (04): : 417 - 420
  • [39] ICRF-159 INDUCED ENHANCEMENT OF RADIATION RESPONSE IN COMBINED MODALITY THERAPIES
    KOVACS, CJ
    EVANS, MJ
    BURHOLT, DR
    SCHENKEN, LL
    RADIATION RESEARCH, 1978, 74 (03) : 580 - 580
  • [40] ADJUVANT ORAL RAZOXANE (ICRF-159) IN RESECTABLE COLORECTAL-CANCER
    GILBERT, JM
    HELLMANN, K
    EVANS, M
    CASSELL, PG
    STOODLEY, B
    ELLIS, H
    WASTELL, C
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 8 (03) : 293 - 299
12345